Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

A suite of kinetically superior AEP ligases can cyclise an intrinsically disordered protein.

Harris KS, Guarino RF, Dissanayake RS, Quimbar P, McCorkelle OC, Poon S, Kaas Q, Durek T, Gilding EK, Jackson MA, Craik DJ, van der Weerden NL, Anders RF, Anderson MA.

Sci Rep. 2019 Jul 25;9(1):10820. doi: 10.1038/s41598-019-47273-7.

2.

Modulation of the aggregation of an amyloidogenic sequence by flanking-disordered region in the intrinsically disordered antigen merozoite surface protein 2.

Zhang W, Zhang J, MacRaild CA, Norton RS, Anders RF, Zhang X.

Eur Biophys J. 2019 Jan;48(1):99-110. doi: 10.1007/s00249-018-1337-8. Epub 2018 Nov 15.

PMID:
30443712
3.

Human Immunization With a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains.

Feng G, Boyle MJ, Cross N, Chan JA, Reiling L, Osier F, Stanisic DI, Mueller I, Anders RF, McCarthy JS, Richards JS, Beeson JG.

J Infect Dis. 2018 Jun 5;218(1):35-43. doi: 10.1093/infdis/jiy170.

PMID:
29584918
4.

Lipid interactions modulate the structural and antigenic properties of the C-terminal domain of the malaria antigen merozoite surface protein 2.

Das SC, Morales RAV, Seow J, Krishnarjuna B, Dissanayake R, Anders RF, MacRaild CA, Norton RS.

FEBS J. 2017 Aug;284(16):2649-2662. doi: 10.1111/febs.14135. Epub 2017 Jul 5.

5.

Structure and Characterisation of a Key Epitope in the Conserved C-Terminal Domain of the Malaria Vaccine Candidate MSP2.

Seow J, Morales RA, MacRaild CA, Krishnarjuna B, McGowan S, Dingjan T, Jaipuria G, Rouet R, Wilde KL, Atreya HS, Richards JS, Anders RF, Christ D, Drinkwater N, Norton RS.

J Mol Biol. 2017 Mar 24;429(6):836-846. doi: 10.1016/j.jmb.2017.02.003. Epub 2017 Feb 8.

PMID:
28189425
6.

Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance.

McCallum FJ, Persson KE, Fowkes FJ, Reiling L, Mugyenyi CK, Richards JS, Simpson JA, Williams TN, Gilson PR, Hodder AN, Sanders PR, Anders RF, Narum DL, Chitnis C, Crabb BS, Marsh K, Beeson JG.

J Leukoc Biol. 2017 Apr;101(4):913-925. doi: 10.1189/jlb.5MA0716-294R. Epub 2016 Nov 11.

7.

Structure-Activity Studies of β-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1-RON2 Interaction.

Wang G, Drinkwater N, Drew DR, MacRaild CA, Chalmers DK, Mohanty B, Lim SS, Anders RF, Beeson JG, Thompson PE, McGowan S, Simpson JS, Norton RS, Scanlon MJ.

J Mol Biol. 2016 Oct 9;428(20):3986-3998. doi: 10.1016/j.jmb.2016.07.001. Epub 2016 Jul 14.

PMID:
27422009
8.

Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.

Krishnarjuna B, Andrew D, MacRaild CA, Morales RA, Beeson JG, Anders RF, Richards JS, Norton RS.

Sci Rep. 2016 Feb 11;6:20613. doi: 10.1038/srep20613.

9.

Antibody Recognition of Disordered Antigens.

MacRaild CA, Richards JS, Anders RF, Norton RS.

Structure. 2016 Jan 5;24(1):148-157. doi: 10.1016/j.str.2015.10.028. Epub 2015 Dec 17.

10.

Insights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions.

Guy AJ, Irani V, MacRaild CA, Anders RF, Norton RS, Beeson JG, Richards JS, Ramsland PA.

PLoS One. 2015 Oct 29;10(10):e0141729. doi: 10.1371/journal.pone.0141729. eCollection 2015.

11.

Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens.

Reddy SB, Anders RF, Cross N, Mueller I, Senn N, Stanisic DI, Siba PM, Wahlgren M, Kironde F, Beeson JG, Persson KE.

BMC Microbiol. 2015 Jul 3;15:133. doi: 10.1186/s12866-015-0461-1.

12.

Structural basis for epitope masking and strain specificity of a conserved epitope in an intrinsically disordered malaria vaccine candidate.

Morales RAV, MacRaild CA, Seow J, Krishnarjuna B, Drinkwater N, Rouet R, Anders RF, Christ D, McGowan S, Norton RS.

Sci Rep. 2015 May 12;5:10103. doi: 10.1038/srep10103.

13.

Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria.

Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, Cheng YS, Stubbs J, Tetteh KK, Conway DJ, McCarthy JS, Muller I, Marsh K, Anders RF, Beeson JG.

Immunity. 2015 Mar 17;42(3):580-90. doi: 10.1016/j.immuni.2015.02.012.

14.

Conformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2.

MacRaild CA, Zachrdla M, Andrew D, Krishnarjuna B, Nováček J, Žídek L, Sklenář V, Richards JS, Beeson JG, Anders RF, Norton RS.

PLoS One. 2015 Mar 5;10(3):e0119899. doi: 10.1371/journal.pone.0119899. eCollection 2015.

15.

Structure and dynamics of apical membrane antigen 1 from Plasmodium falciparum FVO.

Lim SS, Yang W, Krishnarjuna B, Kannan Sivaraman K, Chandrashekaran IR, Kass I, MacRaild CA, Devine SM, Debono CO, Anders RF, Scanlon MJ, Scammells PJ, Norton RS, McGowan S.

Biochemistry. 2014 Nov 25;53(46):7310-20. doi: 10.1021/bi5012089. Epub 2014 Nov 14.

PMID:
25360546
16.

Molecular insights into the interaction between Plasmodium falciparum apical membrane antigen 1 and an invasion-inhibitory peptide.

Wang G, MacRaild CA, Mohanty B, Mobli M, Cowieson NP, Anders RF, Simpson JS, McGowan S, Norton RS, Scanlon MJ.

PLoS One. 2014 Oct 24;9(10):e109674. doi: 10.1371/journal.pone.0109674. eCollection 2014.

17.

Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.

Terheggen U, Drew DR, Hodder AN, Cross NJ, Mugyenyi CK, Barry AE, Anders RF, Dutta S, Osier FH, Elliott SR, Senn N, Stanisic DI, Marsh K, Siba PM, Mueller I, Richards JS, Beeson JG.

BMC Med. 2014 Oct 16;12:183. doi: 10.1186/s12916-014-0183-5.

18.

Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Harris KS, Adda CG, Khore M, Drew DR, Valentini-Gatt A, Fowkes FJ, Beeson JG, Dutta S, Anders RF, Foley M.

Infect Immun. 2014 Nov;82(11):4707-17. doi: 10.1128/IAI.02061-14. Epub 2014 Aug 25.

19.

Ligand-induced conformational change of Plasmodium falciparum AMA1 detected using 19F NMR.

Ge X, MacRaild CA, Devine SM, Debono CO, Wang G, Scammells PJ, Scanlon MJ, Anders RF, Foley M, Norton RS.

J Med Chem. 2014 Aug 14;57(15):6419-27. doi: 10.1021/jm500390g. Epub 2014 Aug 5.

PMID:
25068708
20.

Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.

Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG.

BMC Med. 2014 Jul 1;12:108. doi: 10.1186/1741-7015-12-108.

21.

Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.

Dutta S, Dlugosz LS, Drew DR, Ge X, Ababacar D, Rovira YI, Moch JK, Shi M, Long CA, Foley M, Beeson JG, Anders RF, Miura K, Haynes JD, Batchelor AH.

PLoS Pathog. 2013;9(12):e1003840. doi: 10.1371/journal.ppat.1003840. Epub 2013 Dec 26. Erratum in: PLoS Pathog. 2014 Jan;10(1). doi:10.1371/annotation/be0d67d1-314f-4654-8a2f-b668d1e32bbd. Ge, Xiopeng [corrected to Ge, Xiaopeng].

22.

Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum.

Boyle MJ, Langer C, Chan JA, Hodder AN, Coppel RL, Anders RF, Beeson JG.

Infect Immun. 2014 Mar;82(3):924-36. doi: 10.1128/IAI.00866-13. Epub 2013 Nov 11.

23.

Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.

Mugyenyi CK, Elliott SR, McCallum FJ, Anders RF, Marsh K, Beeson JG.

PLoS One. 2013 Jul 5;8(7):e68304. doi: 10.1371/journal.pone.0068304. Print 2013.

24.

New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women.

Fowkes FJ, McGready R, Cross NJ, Hommel M, Simpson JA, Elliott SR, Richards JS, Lackovic K, Viladpai-Nguen J, Narum D, Tsuboi T, Anders RF, Nosten F, Beeson JG.

J Infect Dis. 2012 Nov 15;206(10):1612-21. doi: 10.1093/infdis/jis566. Epub 2012 Sep 10.

25.

Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2.

Adda CG, MacRaild CA, Reiling L, Wycherley K, Boyle MJ, Kienzle V, Masendycz P, Foley M, Beeson JG, Norton RS, Anders RF.

Infect Immun. 2012 Dec;80(12):4177-85. doi: 10.1128/IAI.00665-12. Epub 2012 Sep 10.

26.

The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi.

Barclay VC, Sim D, Chan BH, Nell LA, Rabaa MA, Bell AS, Anders RF, Read AF.

PLoS Biol. 2012;10(7):e1001368. doi: 10.1371/journal.pbio.1001368. Epub 2012 Jul 31.

27.

Lipid interactions of the malaria antigen merozoite surface protein 2.

MacRaild CA, Pedersen MØ, Anders RF, Norton RS.

Biochim Biophys Acta. 2012 Nov;1818(11):2572-8. doi: 10.1016/j.bbamem.2012.06.015. Epub 2012 Jun 27.

28.

High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria.

Reddy SB, Anders RF, Beeson JG, Färnert A, Kironde F, Berenzon SK, Wahlgren M, Linse S, Persson KE.

PLoS One. 2012;7(2):e32242. doi: 10.1371/journal.pone.0032242. Epub 2012 Feb 21.

29.

Role of the helical structure of the N-terminal region of Plasmodium falciparum merozoite surface protein 2 in fibril formation and membrane interaction.

Zhang X, Adda CG, Low A, Zhang J, Zhang W, Sun H, Tu X, Anders RF, Norton RS.

Biochemistry. 2012 Feb 21;51(7):1380-7. doi: 10.1021/bi201880s. Epub 2012 Feb 8.

PMID:
22304430
30.

A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.

McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, Tierney E, Aked-Hurditch H, Adda C, Cross N, Richards JS, Fowkes FJ, Boyle MJ, Long C, Druilhe P, Beeson JG, Anders RF.

PLoS One. 2011;6(9):e24413. doi: 10.1371/journal.pone.0024413. Epub 2011 Sep 19.

31.

EGCG disaggregates amyloid-like fibrils formed by Plasmodium falciparum merozoite surface protein 2.

Chandrashekaran IR, Adda CG, Macraild CA, Anders RF, Norton RS.

Arch Biochem Biophys. 2011 Sep 15;513(2):153-7. doi: 10.1016/j.abb.2011.07.008. Epub 2011 Jul 19.

32.

Apical membrane antigen 1 as an anti-malarial drug target.

Macraild CA, Anders RF, Foley M, Norton RS.

Curr Top Med Chem. 2011;11(16):2039-47. Review.

PMID:
21619512
33.

The case for a subunit vaccine against malaria.

Anders RF.

Trends Parasitol. 2011 Aug;27(8):330-4. doi: 10.1016/j.pt.2011.04.003. Epub 2011 May 17.

PMID:
21592861
34.

Peptide inhibitors of the malaria surface protein, apical membrane antigen 1: identification of key binding residues.

Lee EF, Yao S, Sabo JK, Fairlie WD, Stevenson RA, Harris KS, Anders RF, Foley M, Norton RS.

Biopolymers. 2011 May;95(5):354-64. doi: 10.1002/bip.21582. Epub 2011 Jan 6.

35.

Inhibition by flavonoids of amyloid-like fibril formation by Plasmodium falciparum merozoite surface protein 2.

Chandrashekaran IR, Adda CG, MacRaild CA, Anders RF, Norton RS.

Biochemistry. 2010 Jul 20;49(28):5899-908. doi: 10.1021/bi902197x.

PMID:
20545323
36.

Identification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2).

Yang X, Adda CG, MacRaild CA, Low A, Zhang X, Zeng W, Jackson DC, Anders RF, Norton RS.

Biochimie. 2010 Oct;92(10):1287-95. doi: 10.1016/j.biochi.2010.06.001. Epub 2010 Jun 11.

37.

Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum.

Anders RF, Adda CG, Foley M, Norton RS.

Hum Vaccin. 2010 Jan;6(1):39-53. Epub 2010 Jan 19. Review.

PMID:
20061790
38.

Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils.

Adda CG, Murphy VJ, Sunde M, Waddington LJ, Schloegel J, Talbo GH, Vingas K, Kienzle V, Masciantonio R, Howlett GJ, Hodder AN, Foley M, Anders RF.

Mol Biochem Parasitol. 2009 Aug;166(2):159-71. doi: 10.1016/j.molbiopara.2009.03.012. Epub 2009 Apr 9.

39.

FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan.

Nasr A, Iriemenam NC, Giha HA, Balogun HA, Anders RF, Troye-Blomberg M, ElGhazali G, Berzins K.

Malar J. 2009 Mar 13;8:43. doi: 10.1186/1475-2875-8-43.

40.

Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.

Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG.

Infect Immun. 2009 Mar;77(3):1165-74. doi: 10.1128/IAI.01129-08. Epub 2009 Jan 12.

41.

Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

Iriemenam NC, Khirelsied AH, Nasr A, ElGhazali G, Giha HA, Elhassan A-Elgadir TM, Agab-Aldour AA, Montgomery SM, Anders RF, Theisen M, Troye-Blomberg M, Elbashir MI, Berzins K.

Vaccine. 2009 Jan 1;27(1):62-71. doi: 10.1016/j.vaccine.2008.10.025. Epub 2008 Oct 31.

PMID:
18977268
42.

Mixed allele malaria vaccines: host protection and within-host selection.

Barclay VC, Chan BH, Anders RF, Read AF.

Vaccine. 2008 Nov 11;26(48):6099-107. doi: 10.1016/j.vaccine.2008.09.004. Epub 2008 Sep 18.

43.

The impact of immunization on competition within Plasmodium infections.

Grech K, Chan BH, Anders RF, Read AF.

Evolution. 2008 Sep;62(9):2359-71. doi: 10.1111/j.1558-5646.2008.00438.x. Epub 2008 Jun 6.

PMID:
18540947
44.

Solution conformation, backbone dynamics and lipid interactions of the intrinsically unstructured malaria surface protein MSP2.

Zhang X, Perugini MA, Yao S, Adda CG, Murphy VJ, Low A, Anders RF, Norton RS.

J Mol Biol. 2008 May 23;379(1):105-21. doi: 10.1016/j.jmb.2008.03.039. Epub 2008 Mar 28.

45.

Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition.

Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH, Gupta A, Bai T, Murphy VJ, Anders RF, Foley M, Nuttall SD.

Structure. 2007 Nov;15(11):1452-66.

46.

Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.

Coley AM, Gupta A, Murphy VJ, Bai T, Kim H, Foley M, Anders RF, Batchelor AH.

PLoS Pathog. 2007 Sep 7;3(9):1308-19. Erratum in: PLoS Pathog. 2007 Nov;3(11):e172.

47.

A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils.

Yang X, Adda CG, Keizer DW, Murphy VJ, Rizkalla MM, Perugini MA, Jackson DC, Anders RF, Norton RS.

J Pept Sci. 2007 Dec;13(12):839-48.

PMID:
17883245
48.

Merozoite surface protein 2 of Plasmodium falciparum: expression, structure, dynamics, and fibril formation of the conserved N-terminal domain.

Low A, Chandrashekaran IR, Adda CG, Yao S, Sabo JK, Zhang X, Soetopo A, Anders RF, Norton RS.

Biopolymers. 2007 Sep;87(1):12-22.

PMID:
17516503
49.

Abundance of intrinsically unstructured proteins in P. falciparum and other apicomplexan parasite proteomes.

Feng ZP, Zhang X, Han P, Arora N, Anders RF, Norton RS.

Mol Biochem Parasitol. 2006 Dec;150(2):256-67. Epub 2006 Sep 20.

PMID:
17010454
50.

The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.

Coley AM, Parisi K, Masciantonio R, Hoeck J, Casey JL, Murphy VJ, Harris KS, Batchelor AH, Anders RF, Foley M.

Infect Immun. 2006 May;74(5):2628-36.

Supplemental Content

Loading ...
Support Center